Figure 2.

Prevention of eosinophilia by EPS-treated dendritic cells.(A) Timeline for BMDC incubation with exopolysaccharide and HDM prior to i.n. transfer into 7–10 week-old C57Bl/6 mice. BMDC were generated from C57Bl/6 mouse bone marrow in the presence of 20ng/mL granulocyte-macrophage colony-stimulating factor (GM-CSF) for 6 days to >85% CD11c+ purity. Dendritic cell transfer groups included 1) No Treatment (No Txt) with BMDC receiving neither EPS nor HDM 2) HDM group with BMDC receiving HDM alone on D-2 and 3) EPS + HDM group of BMDC receiving EPS on D-2, followed by HDM on D-1. (B-E) Quantification of cells from BAL cytospun and stained with DiffQuick on Day 14. Data represent mean ± SEM (n = 3). *** p < 0.0005, ** p < 0.005, * p < 0.05 by Student t test. i.n.= intranasal. These data are representative of 4 independent BMDC transfer experiments.